Literature DB >> 24157031

Long-term outcome of liver transplantation for combined hepatocellular carcinoma and cholangiocarcinoma.

Y-H Park1, S Hwang, C-S Ahn, K-H Kim, D-B Moon, T-Y Ha, G-W Song, D-H Jung, G-C Park, J-M Namgoong, C-S Park, H-W Park, S-H Kang, B-H Jung, S-G Lee.   

Abstract

PURPOSE: Combined hepatocellular carcinoma (HCC) and cholangiocellular carcinoma (CCC) is a rare pair of intrahepatic malignancies. Differential diagnosis among combined HCC-CCC, HCC, or CCC can be difficult; thus malignancies other than ordinary HCC are occasionally encountered unexpectedly in explanted liver specimens. The present study analyzed the long-term outcomes of liver transplantation (OLT) among patients with HCC-CCC.
METHODS: Between January 1999 and December 2009, we performed 2137 adult OLT at our institution including 15 cases of pathologically confirmed HCC-CCC, who all underwent OLT with a pretransplant diagnosis of HCC. We reviewed retrospectively the medical records of these 15 patients.
RESULTS: Their mean age was 58.9 ± 7.2 years. The median preoperative alpha-fetoprotein level was 32.6 ng/mL. Fourteen patients underwent living donor and one deceased donor OLT. The Milan criteria were met in 12 cases. A single tumor was identified in 8 and multiple lesions in 7 patients. The maximal tumor diameter was 2.9 ± 1.7 cm. Seven patients experienced tumor recurrences: including 6 within the first 12 months. All of the patients who experienced recurrences died at a median 4 months after that diagnosis. The overall patient survival rates were 66.7% at 1 year and 60.0% at 3 and 5 years. Disease-free patient survival rates were 60.0% at 1 year and 53.3% at 3 and 5 years.
CONCLUSIONS: Patients with combined HCC-CCC showed a high rate of early recurrences, particularly within the first year.
Copyright © 2013. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2013        PMID: 24157031     DOI: 10.1016/j.transproceed.2013.08.056

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  11 in total

1.  Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy.

Authors:  Jane E Rogers; Ryan M Bolonesi; Asif Rashid; Khaled M Elsayes; Mohamed G Elbanan; Lindsey Law; Ahmed Kaseb; Rachna T Shroff
Journal:  J Gastrointest Oncol       Date:  2017-04

2.  Postresection Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Authors:  Young-In Yoon; Shin Hwang; Young-Joo Lee; Ki-Hun Kim; Chul-Soo Ahn; Deok-Bog Moon; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Jong-Woo Lee; Seung-Mo Hong; Eun Sil Yu; Sung-Gyu Lee
Journal:  J Gastrointest Surg       Date:  2015-12-01       Impact factor: 3.452

Review 3.  Impact of incidental/misdiagnosed intrahepatic cholangiocarcinoma and combined hepatocellular cholangiocarcinoma on the outcomes of liver transplantation: an institutional case series and literature review.

Authors:  Rahul Gupta; Junichi Togashi; Nobuhisa Akamatsu; Yoshihiro Sakamoto; Norihiro Kokudo
Journal:  Surg Today       Date:  2017-01-25       Impact factor: 2.549

4.  Management of combined hepatocellular carcinoma-cholangiocarcinoma.

Authors:  Ju Dong Yang; Lewis R Roberts
Journal:  Curr Hepatol Rep       Date:  2018-10-17

5.  Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database.

Authors:  Valery Vilchez; Malay B Shah; Michael F Daily; Luis Pena; Ching-Wei D Tzeng; Daniel Davenport; Peter J Hosein; Roberto Gedaly; Erin Maynard
Journal:  HPB (Oxford)       Date:  2016-01-07       Impact factor: 3.647

6.  Hepatocholangiocarcinoma/intrahepatic cholangiocarcinoma: are they contraindication or indication for liver transplantation? A propensity score-matched analysis.

Authors:  Ka Wing Ma; Kenneth Siu Ho Chok; Wong Hoi She; Tan To Cheung; Albert Chi Yan Chan; Wing Chiu Dai; James Yan Yue Fung; Chung Mau Lo
Journal:  Hepatol Int       Date:  2018-02-15       Impact factor: 6.047

7.  Effect of liver transplantation in combined hepatocellular and cholangiocellular carcinoma: a case series.

Authors:  Di Wu; Zhong-Yang Shen; Ya-Min Zhang; Jian Wang; Hong Zheng; Yong-Lin Deng; Cheng Pan
Journal:  BMC Cancer       Date:  2015-04-08       Impact factor: 4.430

Review 8.  Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma.

Authors:  Shweta Gera; Mark Ettel; Gabriel Acosta-Gonzalez; Ruliang Xu
Journal:  World J Hepatol       Date:  2017-02-28

9.  The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection.

Authors:  Seong Kyun Na; Gwang Hyeon Choi; Han Chu Lee; Yong Moon Shin; Jihyun An; Danbi Lee; Ju Hyun Shim; Kang Mo Kim; Young-Suk Lim; Young-Hwa Chung; Yung Sang Lee
Journal:  PLoS One       Date:  2018-06-07       Impact factor: 3.240

10.  Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study.

Authors:  Maëva Salimon; Caroline Prieux-Klotz; David Tougeron; Vincent Hautefeuille; Morgane Caulet; Jérôme Gournay; Tamara Matysiak-Budnik; Jaafar Bennouna; Manuela Tiako Meyo; Thierry Lecomte; Aziz Zaanan; Yann Touchefeu
Journal:  Br J Cancer       Date:  2017-11-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.